Granulocyte Colony-Stimulating Factor: Definition and What Studies Report

Definition

Granulocyte colony-stimulating factor (G-CSF) is a glycoprotein cytokine — a signalling protein — that acts on haematopoietic progenitor cells in bone marrow to promote the production, maturation, survival and release of neutrophils, a type of white blood cell in the granulocyte family. The name is descriptive rather than structural: in classic colony-forming assays, the factor stimulated the growth of colonies of granulocytes, and the label stuck. G-CSF is also written as CSF3 (the gene symbol) and is frequently abbreviated to G-CSF in clinical and laboratory writing. Its receptor, G-CSF receptor (CSF3R), is expressed on neutrophil precursors and mature neutrophils, and signalling through that receptor is the canonical route by which the cytokine exerts its effects.

What Class of Molecule Is It, and Where Does It Come From?

G-CSF is a single-chain glycosylated polypeptide of roughly 175 amino acids in its native human form, placing it in the cytokine/growth-factor class rather than the small synthetic peptide class that most peptide glossaries cover. It is substantially larger than research peptides such as BPC-157 or the growth hormone secretagogues, and it folds into a four-helix bundle typical of haematopoietic cytokines. Because of that size and its glycosylation, it is usually described as a protein or cytokine, though it sits on the same continuum of biologically active polypeptides.

Endogenously, G-CSF is produced by monocytes, macrophages, endothelial cells, fibroblasts and bone marrow stromal cells, typically in response to inflammatory signals such as bacterial products and pro-inflammatory cytokines. Levels rise during infection, which is consistent with its role as a demand-driven amplifier of neutrophil output. Beyond normal physiology, some tumours acquire the ability to secrete G-CSF ectopically — a phenomenon documented across several organ systems in the case-report literature and discussed below. Laboratory and pharmaceutical forms are produced recombinantly in bacterial or mammalian expression systems; these recombinant versions, and their longer-acting pegylated derivatives, are the forms named in most clinical publications.

How the Term Is Used in Peptide and Biomedical Research

In research writing, "granulocyte colony-stimulating factor" is used in at least four distinguishable ways, and confusing them is a common source of misreading a paper's abstract:

• As an endogenous cytokine — a measurable analyte in serum or tissue, studied as part of inflammatory signalling.
• As a tumour product — describing "G-CSF-producing" cancers, where the tumour itself secretes the cytokine and the patient presents with a markedly elevated neutrophil count without infection.
• As an administered agent — recombinant G-CSF given in clinical settings, with the associated literature on observed reactions.
• As an experimental intervention in animal or tissue models — for example, applied locally to bone or examined in models of autoimmune kidney disease.

Related terminology that appears alongside it includes GM-CSF (granulocyte-macrophage colony-stimulating factor, a distinct cytokine with a broader lineage effect), CSF3R (the receptor gene), and "leukocytosis" or "neutrophilia" (the laboratory findings often reported in G-CSF-related case descriptions).

What the Published Literature Reports

G-CSF-producing tumours

A recurring theme in the case literature is the tumour that secretes G-CSF ectopically. Researchers described a G-CSF-producing bladder cancer in a 2019 case report in Case Reports in Oncology (PMID 31543775), and a comparable G-CSF-producing gallbladder cancer was reported in Acta Medica Okayama in 2016 (PMID 27777433). A 2021 report in In Vivo documented a G-CSF-producing oropharyngeal squamous cell carcinoma (PMID 33910863), and a 2024 report in the Journal of Surgical Case Reports described a G-CSF-producing lung cancer complicated by antiphospholipid antibody syndrome (PMID 38817796). Haematological malignancy has also been implicated: a 2023 Japanese-language report described G-CSF-producing multiple myeloma that presented with neutrophilia (PMID 37673624). Collectively these are single-patient descriptions rather than controlled series, and they document an association between tumour-derived G-CSF and elevated neutrophil counts rather than establishing frequency.

G-CSF and Vascular Inflammation: What Studies Report

The second substantial cluster in the published record concerns large-vessel inflammation described after G-CSF administration. A 2020 report in Internal Medicine described migratory aortitis associated with granulocyte-colony-stimulating factor (PMID 32188815), and a 2023 report in the same journal documented G-CSF-associated aortitis identified on gallium scintigraphy (PMID 36948620). A 2020 case in VASA reported large-vessel vasculitis secondary to granulocyte-colony stimulating factor (PMID 32452726), while a 2022 Respirology Case Reports entry described a "double-ring sign" on imaging in G-CSF-induced vasculitis (PMID 35601806). A further 2022 report in IJU Case Reports described G-CSF-associated arteritis in a patient with castration-resistant prostate cancer (PMID 35005466). These are uncontrolled individual reports; they document that the association has been observed and imaged, not how often it occurs.

Experimental and model work

Outside oncology and vascular case reporting, the verified literature includes model-based work. A 2021 paper in Immunity, Inflammation and Disease reported that granulocyte colony-stimulating factor was not pathogenic in lupus nephritis (PMID 33960699), a negative finding relevant to hypotheses linking neutrophil-driving cytokines to autoimmune kidney injury. In a different domain entirely, a 2017 study in Clinical Oral Implants Research examined the influence of locally applied granulocyte-colony stimulating factor on osteoporotic bone (PMID 27038192), illustrating that the cytokine has been investigated as a local as well as systemic signal.

Quick Reference Table

How to Read This Literature

Most of the G-CSF material summarised above consists of case reports — the weakest design for estimating how commonly something happens, but a useful one for establishing that a phenomenon has been observed and characterised. A case report of aortitis following G-CSF, for example, cannot quantify risk; it documents a temporal association in one patient with supporting imaging. Similarly, a report of a G-CSF-producing gallbladder or bladder cancer establishes that ectopic secretion occurs in that tumour type without indicating prevalence. Model studies such as the lupus nephritis work and the local bone application study are experimental, but their findings apply to the specific model and endpoints used and do not transfer automatically to human physiology.

Readers comparing sources should also keep G-CSF distinct from GM-CSF. The two cytokines share a naming convention and an interest in myeloid lineages, but they act through different receptors and have different described biology; abstracts occasionally abbreviate in ways that invite confusion.

Educational Note

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical condition, medication, or laboratory finding. Nothing here describes how any substance should be obtained, prepared or administered, and no dosing information is provided because the verified sources cited are definitional, observational or model-based rather than dosing studies. Recombinant G-CSF products are regulated prescription biologics in most jurisdictions, and material sold as a research chemical is labelled for research use only.

References

• Granulocyte Colony-Stimulating Factor-Producing Bladder Cancer (Case Reports in Oncology, 2019)
• Granulocyte Colony-Stimulating Factor-Producing Gallbladder Cancer (Acta Medica Okayama, 2016)
• Granulocyte Colony-stimulating Factor Producing Oropharyngeal Squamous Cell Carcinoma (In Vivo, 2021)
• Granulocyte colony-stimulating factor-producing lung cancer complicated with antiphospholipid antibody syndrome: a case report (Journal of Surgical Case Reports, 2024)
• [Granulocyte-colony stimulating factor-producing multiple myeloma presenting with neutrophilia] (Rinsho Ketsueki, 2023)
• Migratory Aortitis Associated with Granulocyte-colony-stimulating Factor (Internal Medicine, 2020)
• Granulocyte Colony-stimulating Factor-associated Aortitis on Gallium Scintigraphy (Internal Medicine, 2023)
• Large vessel vasculitis secondary to granulocyte-colony stimulating factor (VASA, 2020)
• Double-ring sign in granulocyte colony-stimulating factor-induced vasculitis (Respirology Case Reports, 2022)
• Granulocyte colony-stimulating factor associated arteritis in a patient with castration-resistant prostate cancer (IJU Case Reports, 2022)
• Granulocyte colony-stimulating factor is not pathogenic in lupus nephritis (Immunity, Inflammation and Disease, 2021)
• The influence of locally applied granulocyte-colony stimulating factor on osteoporotic bone (Clinical Oral Implants Research, 2017)